© 2000 American Heart Association, Inc.
Thrombosis |
Progressive and Transient Expression of Tissue Plasminogen Activator During Fetal Development
From the Departments of Molecular and Experimental Medicine (E.G.L.) and Immunology (C.L.B., G.C.N.P.), The Scripps Research Institute, La Jolla, Calif.
Correspondence to Eugene G. Levin, PhD, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037. E-mail glevin{at}scripps.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—In previous studies of the role of tissue plasminogen activator (tPA) in the lung inflammatory response, we observed that tPA expression was present exclusively in the small arteries and arterioles within the lung and absent from the capillaries, veins, and large pulmonary arteries. To define more completely the expression pattern of tPA, we evaluated the distribution of this protein during prenatal and postnatal development. tPA was first observed in the rat fetus at day 13 in the large arteries of both the thoracic and cranial cavities, including the dorsal aortas and pulmonary arteries in the former and the internal carotid and middle cerebral arteries in the latter. By day 15, tPA was no longer detectable in the aortas but appeared throughout the pulmonary, subclavian, vertebral, and basilar arteries. At day 17, tPA had disappeared from the subclavian artery and the proximal portion of the vertebral artery but was found in the smaller arterial branches of these 2 large vessels. By the end of gestation, tPA had also disappeared from the main pulmonary arteries but remained in the branches at the hilus of the lung. At birth, tPA was concentrated in the endothelia of arteries within the pia mater, the basilar and superficial cerebral arteries, and the lung arterial system. As the animals reached maturity, tPA disappeared from the larger cerebral arteries and their cortical branches but continued to be expressed in the vessels of the pia mater and lung. This study indicates that tPA expression is a dynamic process that responds to a changing arterial environment during vascular development.
Key Words: tissue plasminogen activator • arteries • rat fetus • endothelial cells
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Numerous studies have established that endothelial cells play a pivotal role in the physiology and pathology of the vascular system.1 2 These cells express a variety of proteins that maintain the structural integrity of the vessel wall, inhibit or promote initiation of the coagulation cascade, and mediate the inflammatory response, as well as other dynamic changes in the vasculature during pathological events. The expression of these proteins in some cases is limited to specific vascular beds or tissues. For example, endothelial cells forming the blood-brain barrier demonstrate complex, tight junctions and specialized transport proteins3 4 ; in lymphoid tissues, the high endothelium consists of cells that express unique adhesion molecules for the attachment of lymphocytes,5 whereas the endothelia of postcapillary venules mediate adhesive interactions between leukocytes and the vessel wall.6 Recent studies have suggested that tissue plasminogen activator (tPA) is another endothelial cell protein expressed in a specific location within the vascular system. Since its discovery, tPA has been considered the primary activator of the blood fibrinolytic system.7 Plasma tPA has always been thought to be a product of the endothelial cells of all vessels, a conclusion resulting from studies with cultured endothelial cells derived from a variety of tissues and organs.8 9 The validity of this premise, however, is brought into question by recent studies that indicate that tPA is not associated with all endothelia in vivo. Examination of the mouse lung during the inflammatory response clearly showed that both tPA mRNA and protein were absent from endothelial cells of the capillary and venous beds within the lung.10 Even under hyperoxic conditions in which the number of vessels expressing endothelial cell tPA increased, tPA was associated only with the arteries. In addition, the large pulmonary artery was also devoid of tPA, indicating that cells that have been used historically for the study of tPA regulation in vitro may not be producers of this protein in vivo. In contrast to early assumptions about the systemic function of tPA in hemostasis and endothelial cell biology, these results raise the possibility that the role of tPA is more localized and more specific than previously thought.
To determine whether our interpretation of these early studies is correct, ie, that endothelial cell tPA is not the product of endothelial cells in general but provides a more defined role in hemostasis, we assessed the expression pattern of the protein throughout the course of fetal development and after birth. The results demonstrate that tPA is a product of a select subset of arterial endothelial cells. However, during fetal development, expression starts with the aorta and spreads to and subsequently disappears from a variety of large vessels in the thoracic and cranial cavities. At no time is tPA found in other organs. The final physiological pattern of expression in the adult is confined to the lung and small vessels in the brain, a pattern that suggests a localization more restricted than ever suggested by in vitro studies.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
The tPA antibody used in this study for immunohistochemical analysis of rat tissue was a rabbit polyclonal anti-human tPA IgG provided by Dr Howard Soule, Corvas International, San Diego, Calif. This antibody at 50 µg/mL was capable of neutralizing at least 1 U of tPA activity for 3 hours in fibrin overlay gels but had no effect on urokinase activity. Rabbit polyclonal antibodies to human von Willebrand factor (vWF) were provided by Dr Zaverrio Ruggeri, The Scripps Research Institute, La Jolla, Calif. Monoclonal antibodies against smooth muscle cell actin and detecting antibodies (sheep anti-rabbit IgG or goat anti-mouse IgG conjugated to horseradish peroxidase) were purchased from Sigma Chemical Co. RNA probes to rat tPA were generated from a 400-bp fragment of rat tPA in pGEM provided by Tor Ny, Umea University, Umea, Sweden.
Animal Experimentation
All animal protocols were approved by the Animal Research
Committee (protocol No. ARC48OCT8). Timed pregnant rats (Wistar) were
placed in a chamber containing halothane (Halocarbon Inc) until
respiration ceased, the abdominal cavity was exposed, and the uterus
was removed. The fetuses were separated and immediately placed in
aqueous zinc fixative consisting of 0.5% zinc acetate, 0.5%
ZnCl2, 0.1 mol/L Tris chloride, pH 7.4, and
0.05% calcium acetate.11 Fetuses of 12 to 15 days’
gestation were fixed whole for 24 hours, whereas older fetuses were
sectioned at the neck and lower thorax and placed in fixative for 48
hours to allow for complete penetration of the fixative. Prolonged
immersion in the fixative had no effect on the antigenic properties of
tPA (data not shown). For in situ hybridization, the tissue was fixed
with zinc formalin for 4 to 6 hours. The tissue was paraffin-embedded,
sectioned to 6-µm thickness, and placed on glass slides (Superfrost
Plus, Fisher Scientific Co). Alternatively, the tissue was flash-frozen
in LN2. Ovaries were obtained from 5-week-old
rats and immediately frozen in
LN2.12
Immunohistochemical Staining
For immunohistochemical analysis, tissue sections were
dewaxed in xylene, rehydrated, and incubated with 20% nonimmune goat
serum (Sigma Chemical Co) for 30 minutes at 37°C. The serum was
removed and the tissues incubated with the appropriate dilutions of
anti-tPA, anti-vWF, or anti-actin antibody overnight at 4°C. After
being washed with PBS, biotinylated sheep anti-rabbit IgG or goat
anti-mouse IgG (1:50, Sigma Chemical Co) was added for 30 minutes at
37°C, and the slides were washed and then treated with 3%
H2O2 for 20 minutes at room
temperature. Antigen-antibody complexes were detected by incubation
with Extr-Avidin-peroxidase (1:600, Sigma Chemical Co) for 30 minutes
at 37°C, followed by addition of 3-amino-9-ethylcarbazole for 10
minutes at 37°C. All slides were counterstained with hematoxylin. The
antigen was visualized as a red precipitate.
Immunostaining of a sequentially cut tissue section
with nonimmune rabbit IgG was performed in parallel as a negative
control in each experiment. Preadsorbtion of the antibody with purified
recombinant tPA (Activase, Genentech) eliminated staining of the
tissue, validating the specificity of binding to tPA. Photographs were
taken with a Nikon 6006 camera on a Zeiss Axiolab microscope at 50 to
400 magnification.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Developing embryos starting at day 12 were fixed, serially sectioned, and immunostained for tPA to determine the expression pattern during development. At day 12, no tPA antigen was detected in any of the blood vessels despite the fact that the endothelia of all arteries examined had produced and stored vWF (data not shown). Within the next 24 hours, during day 13, the endothelia of various vessels in the thoracic and cranial cavities begin to produce tPA (Figure 1
). The endothelia of the
dorsal aorta were positive for tPA, although the corresponding cells of
the cardinal vein, within the same plane and in the same surrounding
environment, were not (Figure 1C). tPA expression was continuous
from the aortas into the subclavian (data not shown) and vertebral
(Figures 1A and 1D; va) arteries. Moving cranially, we also
observed tPA expression in the entire length of the internal carotid
artery (which forms the rostral extension of the dorsal aorta at this
stage) and the middle cerebral arteries (Figures 1B and 1D). In
each case, smooth muscle cell migration into the surrounding tissue had
occurred, although the vessel wall remained immature, containing only a
single layer. Figure 1C demonstrates early tPA expression within
the endothelial cells of each pulmonary artery.
tPA expression was absent from the arteries of various other organs,
including the heart, liver, and kidneys (data not shown).
|
By day 15 (Figures 2 and 3), endothelial cell tPA
expression disappeared from the aorta but continued to be observed in
the arterial endothelia of the pulmonary, cranial,
cervical, and thoracic arteries as they developed and elongated.
Despite its absence from the aorta, tPA appeared at the junction of the
aorta and subclavian artery (Figure 2A; s) and continued to be
detectable along the entire length of the vertebral artery (Figure 2A; v). The main pulmonary arteries also remained
positive for tPA antigen (Figure 2C; p) as well as the
endothelia of arteries developing within the lung parenchyma (Figure 2C; pi). In contrast, the common carotid arteries (Figure 2B; cc), another major branch of the aorta within close
proximity to the subclavian, were negative for tPA expression. tPA was
now absent in the internal carotid artery after its divergence from the
common carotid. This feature is demonstrated in Figure 3D, which shows the lower extremity of the internal carotid artery
(ic) within the same plane as the cochlear canals. However, as the
internal carotid artery extends caudally and decreases in diameter, tPA
appears in its endothelium and continues to be
expressed into the middle cerebral artery (Figure 3E; ic
and mc). At this level, the internal carotid artery is juxtaposed to
the base of the brain (notice the pituitary, p). Thus, tPA-positive and
tPA-negative cells are found within the same artery
(represented by sections d and e in the diagram of
the fetus). Also shown in Figure 3D is a section of the medulla,
demonstrating that the endothelia of the vertebral arteries (v), the
basilar artery (b), and the cerebellar arteries (c) are all positive
for tPA. tPA expression was not confined to these larger arteries; the
arterioles (Figure 3F; a) formed from the middle cerebral artery
and surrounding the ventricular system express tPA. This
finding is in contrast to the small veins that are present within
the same plane and are of similar size (v).
|
|
By day 17, both the vertebral and subclavian arteries within the
thoracic cavity became devoid of tPA (Figures 4A and 4C). However, tPA expression
appeared in a branch of the vertebral artery, a pattern (ie,
branch-point stimulation) that we have found to occur in different
vascular beds during development and in the mature
animal.10 Despite the absence of tPA from the vertebral
arteries at the proximal region, the protein reappeared as the
vertebral arteries extended caudally toward the brain (Figure 4D; v), in a similar fashion to that observed with the
internal carotid artery at day 15 (Figure 3F
). Thus, tPA
expression is not simply a function of the type of vessel in which the
endothelial cells are found but may respond to factors
that change throughout the length of a single artery.
|
After day 17, we did not observe any major changes in the pattern of
tPA expression save one. By day 20, tPA disappeared from the endothelia
of the large pulmonary arteries (Figure 4B; pa)
but continued to be expressed as they branched into the lung
parenchyma, another example of branch-point stimulation. At this time,
the pulmonary arteries that align with the bronchi and
bronchioles were all expressing tPA. This result establishes the
distribution of tPA within the pulmonary system that exists
into adulthood.10
After birth, tPA is exclusively associated with the arteries of the
pulmonary system and the central nervous system. Within the
central nervous system, tPA is found in the distal portions of the
major arteries furnishing blood to the brain, including the internal
carotid, vertebral, and basilar arteries as well as other major
branches, such as the anterior and middle cerebral and cerebellar
arteries (not shown). In addition to these larger arteries, the
arterioles of the pia mater, shown at the bottom surface of the brain
section (Figure 5A, filled arrows), also
express tPA. In fact, we have found that the pial vasculature is highly
enriched in tPA throughout the brain, and branches of the pial vessels
continue to express tPA as they infiltrate into the brain parenchyma.
Although the pial vessels are a rich source of tPA, the number of
vessels within the brain parenchyma that contain tPA is minimal. The
number of vessels expressing vWF in the medulla (Figure 5B) was
compared with those expressing tPA (Figure 5A) within serial
sections. It is clear that the number of vessels containing tPA (open
arrows) are few compared with the total number. In sections cut from
the region containing the hippocampus (Figures 5C and 5D), none
of the vessels within the parenchyma were positive for tPA (Figure 4D) when compared with the arteries demonstrated by staining
with smooth muscle cell actin (Figure 4C). The tPA-positive
vessels are associated with the membrane that lines the interface
between the tissue layers. At this stage in development, tPA expression
is largely relegated to the arteries of the pial membrane and large
vessels.
|
As the animals reach adulthood, there is a shift in the types of vessels in the brain that express tPA. At 4 months of age, tPA continues to be observed in vessels of the meninges and appears in a small fraction of vessels within the brain parenchyma (shown in Reference 13 ). In contrast to the pial vessels, the vertebral and basilar arteries as well as the larger cortical branches of the major cerebral arteries become negative (data not shown). Thus, as the animal ages, there appears to be a shift away from tPA expression in the larger arteries supplying blood to the different parts of the organ to the smaller, more localized vessels.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our analysis of endothelial cell tPA expression in the whole animal demonstrates that this is a protein with very limited distribution within the vascular system, being associated with a fraction of the vessels at any 1 time during prenatal and postnatal life. During prenatal development, tPA expression is not static but appears in a progressive and transitory pattern that is restricted to the arterial endothelial cells of the thoracic and cranial cavities (a summary of the data in graphic form is shown in Figure 6
). tPA
first appeared on the 13th day in the endothelia of the dorsal aortas,
the subclavian arteries, and the internal carotid arteries (which at
this time form the rostral extremity of the aorta). Within 24 hours,
the aortic endothelia were no longer positive, but expression had
spread to the larger arteries supplying the brain (vertebral, basilar,
and middle cerebral) as well as the main pulmonary arteries. By
the end of gestation, tPA expression had disappeared from all of the
vessels of the thoracic cavity, except the arteries within the lung,
but remained in vessels closely associated with tissues of the central
nervous system: the vertebral, internal carotid, middle cerebral, and
spinal arteries and the arterioles of the pia mater. Within a few weeks
of birth, the endothelia of all of the larger vessels, including the
vertebral and basal arteries and the larger cerebral vessels, were no
longer expressing tPA. In addition to establishing that tPA expression
is narrowly distributed within the vascular system, the data
also suggest that the function of tPA may be far more limited than
previously assumed. Since its discovery, tPA has been considered to be
the primary activator of the blood fibrinolytic
system.7 The dissolution of thrombi was a function of the
tPA-dependent conversion of plasminogen to plasmin that
culminated in the degradation of fibrin and other proteins incorporated
into the clot. This conclusion was based primarily on in vitro studies
and animal studies of the use of tPA in therapeutic
thrombolysis, where tPA was infused into the animal and
its efficacy for dissolving preformed thrombi
measured.14 15 The conclusion that tPA must be the primary
fibrinolytic agent within the vascular system was compromised, however,
by results from tPA-deficient mice, which showed that thrombus
dissolution was not dramatically affected by the absence of
tPA.16 Although the rate of thrombolysis
was reduced, clot resolution did occur. This latter result has been
explained by the concept of redundancy, in which other proteins, such
as the plasminogen activator urokinase, with
similar or identical functions, replace the function of the targeted
protein. However, with the results presented here, we propose
that this may not be the case, and that localized proteolysis, and not
systemic vascular fibrinolysis, is the
primary function of tPA. One question that remains, however, is whether
the absence of tPA in the endothelium is due to a true
lack of expression or whether tPA antigen is below the level of
detection. Previously published reports describing selective tPA
expression in the arterioles of the adult lung suggest that the former
possibility is likely the case.10 In those studies,
lung sections were analyzed immunohistochemically, by in situ
hybridization, and by fibrin overly activity measurements. In all 3
cases, tPA antigen, mRNA, and activity were found only in the
endothelium of the pulmonary arteriole system
and colocalized in all cases. Fibrin overlay assays have the advantage
of allowing long-term incubation of the sections (days) and are highly
sensitive to small amounts of plasminogen
activator. These data, although not conclusively proving
the absence of tPA, strongly support our proposal that tPA is expressed
only in the endothelial cells displaying positive
antibody staining.
|
We also suggest that the reproducible pattern of expression in the lung and pia mater represents constitutive expression of tPA. However, we have shown that stimulation of tPA expression in vivo can also occur, eg, during hyperoxia, which induces an increase in tPA expression in other arterioles within the lung parenchyma.10 Thus, even when tPA expression can be stimulated, it is found only in the vessels that it is associated with under normal conditions.
The rapid changes in tPA expression within the same vessels during vascular development suggest that the control of tPA gene expression is influenced by changing environments as the fetus matures, rather than sublineage (clonality) of the endothelial cells,17 18 although the regulatory network controlling localized tPA production might be lineage-specific. The environments must themselves be highly localized and selective for small areas within the vascular system. In some cases, the apparent differences in environment are easily discernible. For example, the branch points between the vertebral artery and its branches and the bifurcation of the main pulmonary artery at the hilus of the lung are areas in which sudden and dramatic changes occur in vessel size and luminal hemodynamics. Changes in vessel wall shear and pressure are known to promote the gene transcription of tPA in endothelial cells via defined regulatory elements.19 20 On the other hand, the appearance of tPA in the distal but not proximal extremities of the vertebral and internal carotid arteries does not have an obvious explanation. No branching, bifurcation of the vessel, or sudden change in orientation occurs, although luminal diameter does narrow gradually as the vessels approach the cranium. Our previous work suggests that vessel size may be a factor in tPA expression.13 In a study of the relationship between tPA and the vasculature of the brain, it was found that although very few vessels express tPA (<3%), 90% of those were in vessels between 7 and 30 µm in diameter. Thus, specific vessel diameter or some consequence of that parameter may be a criterion for tPA expression. Another possibility that is being examined is the effect of the brain on these endothelial cells and their expression of tPA. Such a suggestion is based on other examples of endothelial cell gene expression regulated by cell-cell interaction. For example, formation of the blood-brain barrier appears to be a function of the interaction of endothelial cells and astrocytes,21 while the same appears to be true with vWF expression and endothelial cell–myocyte interaction.22 23 Thus, the control of endothelial cell gene expression by environmental factors found within a well-defined vascular bed has been identified.
The problem with attempting to predict which of these factors is responsible for the onset of tPA production is that there are no consistently shared characteristics among vessels of similar types. During development, for example, vessels of similar dimensions and hemostatic conditions as those positive for tPA exist in other organs, but no tPA has been found in these other tissues. The expression of tPA in endothelial cells of the pulmonary and systemic circulation also reduces the possibility of mechanical (ie, pressure) effects as a reason, since the hemostatic properties of these 2 circulatory systems are different. Thus, general physical characteristics of the vessel and its lumen cannot be linked to the control of tPA expression. Therefore, serious consideration must be given to the possibility that brain- and lung-specific factors play an important role in tPA expression. In the end, it is conceivable that a compendium of several factors regulates tPA expression in the endothelial cells of these vessels.
|
Acknowledgments |
|---|
This research was supported in part by National Heart, Lung, and Blood Institute grants HL56775 (to E.G.L.), HL56609 (to G.C.N.P.), and HL55517 (to C.L.B.). The authors would like to thank Margaret Chadwell for her contribution to the histological and immunohistochemical analysis of the tissues and Michelle Williamson, University of California, San Diego, for her design and artistic rendering of Figure 6
. Received December 8, 1999; accepted March 8, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes [Review]. Bioessays. 1994;16:901–906.[Medline] [Order article via Infotrieve]
2. Risau W. Differentiation of endothelium. FASEB J. 1995;9:926–933.[Abstract]
3. Schlosshauer B. The blood brain barrier: morphology, molecules and neurothelin. Bioessays. 1993;15:341–346.[Medline] [Order article via Infotrieve]
4. Bradbury MWB. The blood-brain barrier. Exp Physiol. 1993;78:453–472.[Medline] [Order article via Infotrieve]
5. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today. 1995;16:449–457.[Medline] [Order article via Infotrieve]
6. Granger DN, Korthuis RJ. Physiologic mechanisms of postischemic tissue injury [Review]. Annu Rev Physiol. 1995;57:311–332.[Medline] [Order article via Infotrieve]
7. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost. 1980;43:77–89.[Medline] [Order article via Infotrieve]
8. van Hinsbergh VW, Kooistra T, Emeis JJ, Koolwijk P. Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis. Int J Radiat Biol. 1991;60:261–272.[Medline] [Order article via Infotrieve]
9. van Zonneveld A-J, Chang GTG, van den Berg J, Kooistra T, Verheijen JH, Pannekoek H, Kluft C. Quantification of tissue-type plasminogen activator (t-PA) mRNA in human endothelial-cell cultures by hybridization with a t-PA cDNA probe. Biochem J.. 1986;235:385–390.[Medline] [Order article via Infotrieve]
10. Levin EG, Santell L, Osborn KG. The expression of tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J Cell Sci. 1997;110:139–148.[Abstract]
11. Beckstead JH. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem. 1994;42:1127–1134.[Abstract]
12. Peng X-R, Hsueh AJW, Ny T. Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. Eur J Biochem. 1993;214:147–156.[Medline] [Order article via Infotrieve]
13. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol. 1994;144:855–861.[Abstract]
14. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981;291:590–591.[Medline] [Order article via Infotrieve]
15. Lijnen HR, Collen D. Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment. Biotechnol Ther. 1989;1:273–304.[Medline] [Order article via Infotrieve]
16. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419–424.[Medline] [Order article via Infotrieve]
17. Wang R, Clark R, Bautch VL. Embryonic stem cell-derived cystic embryoid bodies form vascular channels: an in vitro model of blood vessel development. Development. 1992;114:303–316.[Abstract]
18.
Mikawa T, Fischman DA. Retroviral analysis of
cardiac morphogenesis: discontinuous formation of coronary
vessels. Proc Natl Acad Sci U S A. 1992;89:9504–9508.
19. Resnick N, Gimbrone MA. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J.. 1995;9:874–882.[Abstract]
20.
Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF
Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter
contains a cis-acting fluid shear-stress-responsive element.
Proc Natl Acad Sci U S A. 1993;90:4591–4595.
21. Lobrinus JA, Juillerat-Jeanneret L, Darekar P, Schlosshauer B, Janzer RC. Induction of the blood brain barrier specific HT7 and neurothelin epitopes in endothelial cells of the chick chorioallantoic vessels by a soluble factor derived from astrocytes. Brain Res Dev Brain Res. 1992;70:207–211.[Medline] [Order article via Infotrieve]
22. Nishida M, Springhorn JP, Kelly RA, Smith TW. Cell-cell signaling between adult rat ventricular myocytes and cardiac microvascular endothelial cells in heterotypic primary culture. J Clin Invest. 1993;91:1934–1941.
23.
Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW,
Smith TW, Rosenberg RD. Vascular bed-specific expression of an
endothelial cell gene is programmed by the tissue
microenvironment. J Cell Biol. 1997;138:1117–1124.
This article has been cited by other articles:
 |
|
 |
|
  W. C. Aird Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms Circ. Res., February 2, 2007; 100(2): 158 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-L. Pham, A. Franzen, and E. G. Levin NF1 Regulatory Element Functions as a Repressor of Tissue Plasminogen Activator Expression Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 982 - 987. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||